Hepatocellular carcinoma screening: Difference between revisions
No edit summary |
(Mahshid) |
||
Line 22: | Line 22: | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Hepatology]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Surgery]] |
Revision as of 02:00, 27 November 2017
Hepatocellular carcinoma Microchapters |
Differentiating Hepatocellular carcinoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Hepatocellular carcinoma screening On the Web |
American Roentgen Ray Society Images of Hepatocellular carcinoma screening |
Risk calculators and risk factors for Hepatocellular carcinoma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
According to the American Association of Liver Diseases recommendations, screening for hepatocellular carcinoma by ultrasound (US) is recommended among patients with hepatitis B, hepatitis C, and cirrhosis. Screening is also recommended for Asian men over the age of 40, Asian women over the age of 50, and African American.
Screening
Screening for hepatocellular carcinoma by abdominal ultrasound and serum levels of alpha-fetoprotein is recommended for the following populations:
- Patients with hepatitis B
- Patients with hepatitis C
- Patietns with cirrhosis
- Asian men over the age of 40
- Asian women over the age of 50
- African American